EcoDrugPlus

Amine Oxidase Copper Containing 1

Ensembl ID : ENSACLG00000004426
Gene Symbol: AOC1
3 Cross references
233 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSACLG00000027804
Gene Symbol: APP
4 Cross references
206 Possible Orthologues:

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSACLG00000003374
Gene Symbol: LOC113007350
3 Cross references
205 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSACLG00000007608
Gene Symbol: AR
3 Cross references
214 Possible Orthologues:

Androgen Receptor-Like

Ensembl ID : ENSACLG00000024776
Gene Symbol: LOC113034111
2 Cross references
205 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSACLG00000027373
Gene Symbol: AGTR1
3 Cross references
203 Possible Orthologues:

Apelin Receptor A-Like

Ensembl ID : ENSACLG00000026634
Gene Symbol: LOC113026488
3 Cross references
172 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSACLG00000009435
Gene Symbol: APH1A
3 Cross references
193 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSACLG00000017405
Gene Symbol: LOC113029594
2 Cross references
142 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSACLG00000018441
Gene Symbol: APEX1
3 Cross references
214 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s-Type-Like

Ensembl ID : ENSACLG00000015780
Gene Symbol: LOC113018260
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSACLG00000011007
Gene Symbol: ALOX5
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).